| Dr Nathan Michael Weir, MD, PHD | |
|
5160 Socialville Foster Rd, Mason, OH 45040-9842 | |
| (513) 770-3263 | |
| Not Available |
| Full Name | Dr Nathan Michael Weir |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 11 Years |
| Location | 5160 Socialville Foster Rd, Mason, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861735912 | NPI | - | NPPES |
| 0249780 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 35.130393 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Dermatology Group Inc | 6406740141 | 19 |
News Archive
Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).
Acorda Therapeutics, Inc. today announced an analysis of pooled clinical trial results showed patients who were responders to AMPYRA (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed.
Medical Alarm Concepts Holdings, Inc., manufacturer of the MediPendant™, the first fully-monitored medical alarm system that allows you to speak and listen directly through the pendant, announced today it has acquired the controlling rights to U.S. patent numbers RE 41845 and RE 41392.
Scientists from the UK have recently identified an antiviral metabolite 3'-Deoxy-3',4'-didehydro-cytidine as a potential serum biomarker to diagnose active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the medRxiv* preprint server while awaiting peer review.
› Verified 6 days ago
| Entity Name | Wright State Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114920329 PECOS PAC ID: 7618889320 Enrollment ID: O20031103000097 |
News Archive
Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).
Acorda Therapeutics, Inc. today announced an analysis of pooled clinical trial results showed patients who were responders to AMPYRA (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed.
Medical Alarm Concepts Holdings, Inc., manufacturer of the MediPendant™, the first fully-monitored medical alarm system that allows you to speak and listen directly through the pendant, announced today it has acquired the controlling rights to U.S. patent numbers RE 41845 and RE 41392.
Scientists from the UK have recently identified an antiviral metabolite 3'-Deoxy-3',4'-didehydro-cytidine as a potential serum biomarker to diagnose active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the medRxiv* preprint server while awaiting peer review.
› Verified 6 days ago
| Entity Name | The Dermatology Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780617860 PECOS PAC ID: 6406740141 Enrollment ID: O20040212000202 |
News Archive
Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).
Acorda Therapeutics, Inc. today announced an analysis of pooled clinical trial results showed patients who were responders to AMPYRA (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed.
Medical Alarm Concepts Holdings, Inc., manufacturer of the MediPendant™, the first fully-monitored medical alarm system that allows you to speak and listen directly through the pendant, announced today it has acquired the controlling rights to U.S. patent numbers RE 41845 and RE 41392.
Scientists from the UK have recently identified an antiviral metabolite 3'-Deoxy-3',4'-didehydro-cytidine as a potential serum biomarker to diagnose active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the medRxiv* preprint server while awaiting peer review.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nathan Michael Weir, MD, PHD 4998 Gareth Ln, Cincinnati, OH 45241-5909 Ph: (509) 591-2776 | Dr Nathan Michael Weir, MD, PHD 5160 Socialville Foster Rd, Mason, OH 45040-9842 Ph: (513) 770-3263 |
News Archive
Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).
Acorda Therapeutics, Inc. today announced an analysis of pooled clinical trial results showed patients who were responders to AMPYRA (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed.
Medical Alarm Concepts Holdings, Inc., manufacturer of the MediPendant™, the first fully-monitored medical alarm system that allows you to speak and listen directly through the pendant, announced today it has acquired the controlling rights to U.S. patent numbers RE 41845 and RE 41392.
Scientists from the UK have recently identified an antiviral metabolite 3'-Deoxy-3',4'-didehydro-cytidine as a potential serum biomarker to diagnose active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the medRxiv* preprint server while awaiting peer review.
› Verified 6 days ago
Samir B Patel, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5298 Socialville Foster Rd, Mason, OH 45040 Phone: 513-770-4212 Fax: 513-770-4213 | |
Elizabeth E. Uhlenhake, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5298 Socialville Foster Rd, Mason, OH 45040 Phone: 513-770-4212 Fax: 513-770-4213 | |
Kristine Busse Zitelli, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5298 Socialville Foster Rd, Mason, OH 45040 Phone: 513-770-4212 Fax: 513-770-4213 | |
Mona Datta Mislankar, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4834 Socialville Foster Rd Ste 20, Mason, OH 45040 Phone: 513-459-1988 | |
Jessica Caraway Perkins, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5298 Socialville Foster Rd, Mason, OH 45040 Phone: 513-770-4212 |